Bioequivalency Study of Clarithromycin Tablets Under Fed Conditions
Sponsor
Roxane Laboratories (Industry)
Overall Status
Completed
CT.gov ID
NCT00602498
Collaborator
(none)
28
1
Study Details
Study Description
Brief Summary
The objective of this study was the bioequivalence of a potential generic 500 mg clarithromycin tablet formulation compared with Abbott Laboratories 500 mg clarithromycin tablet, Biaxin® following a single 500 mg dose, administered with food.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| N/A |
Study Design
Study Type:
Interventional
Actual Enrollment
:
28 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
A Single Dose, Two-Treatment, Two-Period, Two-Sequence Crossover Bioequivalency Study of 500 mg Clarithromycin Tablets Under Fed Conditions
Study Start Date
:
Mar 1, 2003
Actual Primary Completion Date
:
Mar 1, 2003
Actual Study Completion Date
:
Mar 1, 2003
Outcome Measures
Primary Outcome Measures
- Bioequivalence [Baseline, Two period, Seven day washout]
Eligibility Criteria
Criteria
Ages Eligible for Study:
18 Years
to 45 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
- No clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening.
Exclusion Criteria:
-
Positive test for HIV, Hepatitis B, or Hepatitis C.
-
Treatment with known enzyme altering drugs.
-
History of allergic or adverse response to clarithromycin or any other macrolide antibiotic.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | MDS Pharma Services | Phoenix | Arizona | United States | 85044-5318 |
Sponsors and Collaborators
- Roxane Laboratories
Investigators
- Principal Investigator: Irving E Weston, MD, MDS Pharma Services
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
,
,
ClinicalTrials.gov Identifier:
NCT00602498
Other Study ID Numbers:
- 461-08
First Posted:
Jan 28, 2008
Last Update Posted:
Jan 23, 2018
Last Verified:
Jan 1, 2018